News

By: Michael Monostra In adults living with HIV, those with three or more metabolic risk factors had a higher risk for developing new-onset diabetes than those […]

Data from the REPRIEVE trial suggest there is only a minimal increased risk of diabetes with statins among people with HIV, and in specific, limited groups […]

By John W. McEvoy and Cian Mangan The potential of high-sensitivity cardiac troponin (hs-cTn) assays to augment cardiovascular disease (CVD) prediction in primary prevention has long been an […]

People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of […]

Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, […]

ACTG, a global clinical trials network focused on HIV and other infectious diseases, will present an exploratory analysis from the REPRIEVE trial demonstrating that former and […]

By Alicia Banks, Duke Global Health Institute As Gerald S. Bloomfield, M.D., saw heart patients in Kenya over the past decade, he knew that cardiovascular disease […]

By Ronak Rajani, Roberta Lima Brum, and Vitaliy Androshchuk HIV affects approximately 45 million people worldwide, making it a major ongoing public health challenge. Although antiretroviral […]

By Kathleen V. Fitch, Marissa Diggs, and Steve Grinspoon Due to the remarkable strides in the management and support of PWH, life expectancy now almost parallels […]